This post was originally published on this site Metastatic castration-resistant prostate cancer (CRPC) patients who receive Xtandi (enzalutamide) plus Xofigo (radium-223) in a real-world setting do not experience more fractures or bone-related events than those given Xofigo alone, an observational study shows. This has been a common concern for metastatic CRPC patients, among whom Xofigo…
This post was originally published on this site A blood test that examines a panel of 11 specific proteins could help distinguish between benign tumors and malignant ovarian cancer, reducing the need for unnecessary surgeries and leading to an earlier diagnosis, a study shows. Conducted by researchers at Uppsala University and Sahlgrenska Academy at the…
This post was originally published on this site Scientists discovered a set of genes that work as an “on/off switch” for malignant multiple myeloma cancer cells, which may shed light into new therapeutic targets for the disease, and for other types of cancers with a higher tendency to spread to bones. The findings of the…
This post was originally published on this site Adding Imfinzi (durvalumab) to standard first-line chemotherapy led to a clinically meaningful extension in the overall survival of patients with advanced small cell lung cancer (SCLC), according to results of a Phase 3 clinical trial. The open-label, global CASPIAN trial (NCT03043872) is testing AstraZeneca’s Imfinzi combined with…
This post was originally published on this site The Committee for Medicinal Products for Human Use (CHMP), an arm of the European Medicines Agency , has recommended the approval of Tecentriq (atezolizumab) in combination with the chemotherapy Abraxane (nab-paclitaxel) as a first-line treatment for some advanced triple-negative breast cancers (TNBC). Specifically, the recommendation is for adult patients with…
This post was originally published on this site The Committee for Medicinal Products for Human Use (CHMP), an arm of the European Medicines Agency, has recommended the expansion of the current marketing authorization for Imbruvica (ibrutinib) to include two new indications in the European Union. The first indication is to be used in combination with…
This post was originally published on this site IMV‘s lead candidate, DPX-Survivac, in combination with Keytruda (pembrolizumab) and low-dose intermittent cyclophosphamide, eliminated radiologic traces of cancer cells in one-third of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) patients in a Phase 2 trial, the company announced. The findings from SPiReL (NCT03349450) were shared at the…
This post was originally published on this site “It’s cancer,” my friend said. She had seen a doctor for something unrelated, but now she’s freaking out. Mostly about the money. The tumor they found in her right breast is small, but it’s rocking her world. “I can’t afford time off work,” she said. “And I…
This post was originally published on this site The European Medicines Agency (EMA) has approved Sophiris Bio’s design for a Phase 3 trial to evaluate the potential of topsalysin (PRX302), an investigative agent for localized prostate cancer. The trial plans to enroll 700 men with intermediate risk disease, who will be randomized to either a…
This post was originally published on this site Testing for additional biomarkers along with the well-known biomarker CA125 can improve the detection of early-stage ovarian cancer, a new study shows. The blood-based assay could significantly improve patient survival if ovarian cancers are identified earlier. The study, “Simultaneous Measurement of 92 Serum Protein Biomarkers for the…
